| Literature DB >> 33387628 |
Lip Leong Chong1, Yu Yang Soon2, Cinnie Yentia Soekojo1, Melissa Ooi3, Wee Joo Chng4, Sanjay de Mel5.
Abstract
This study aims to evaluate the efficacy and safety of Daratumumab-based induction therapy (DBI) in newly diagnosed multiple myeloma (MM). We identified four eligible RCTs including 2735 patients. The primary outcomes of RCTs involving transplant eligible (TEMM) and non-transplant eligible MM (NTEMM) were stringent complete response (sCR) and progression-free survival (PFS) respectively. Meta-analysis was performed using random-effects models. DBI improved sCR rates for standard risk (SR) (OR 1.86, 95 % CI 1.41-2.46) but not HiR (high risk) (OR 0.78, 95 % CI 0.41-1.48) (interaction P = 0.01) TEMM. In NTEMM, DBI improved PFS in SR (HR 0.44, 95 % CI 0.35-0.55) but not HiR patients. (HR 0.81, 95 % CI 0.52-1.27) (interaction P = 0.02). In conclusion, while DBI is efficacious in SR patients, there is insufficient data to support a benefit in HiR-MM.Entities:
Keywords: Daratumumab; High cytogenetic risk; Induction therapy; Meta-analysis; Newly diagnosed multiple myeloma
Mesh：
Substances：
Year: 2020 PMID： 33387628 DOI： 10.1016/j.critrevonc.2020.103211
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312